The Latest Breaking News from AstraZeneca

A prominent Thai politician faces up to 20 years in prison following his indictment on Monday for insulting the king and violating a cyber law, after he criticised the government for over-reliance on a royal-owned firm to supply COVID-19 vaccines.

Manufacturing of the vaccine has slowed and further research is stalled

India has begun offering booster doses of COVID-19 vaccine to all adults but is limiting free shots at government centers to front-line workers and people over age 60

The Centre for Covid-19 Situation Administration (CCSA) has approved a plan to procure a long-acting coronavirus antibody cocktail for people with poor immune systems who cannot be vaccinated.

Harbour BioMed has announced a global out-license agreement with AstraZeneca plc (NASDAQ:AZN) for CLDN18.2xCD3 bispecific antibody (HBM7022). HBM7022 is a novel bispecific antibody generated from HBM's HCAb Based Immune Cell Engagers (HBICE) Platform.  HBM7022 is currently in the preclinical stage, which crosslinks tumor cells and T cells by targeting a tumor-associated antigen (Claudin18.2) and…

Here's a roundup of top developments in the biotech space over the last 24 hours:

AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 4.32% on an annualized basis producing an average annual return of 18.01%. Currently, AstraZeneca has a market capitalization of $214.04 billion.

AstraZeneca Plc (NASDAQ:AZN) shared new and prolonged follow-up results from the Phase 3 CHAMPION-MG trial open-label extension (OLE) of Ultomiris (ravulizumab-cwvz) in generalized myasthenia gravis (gMG). Ultomiris demonstrated long-term efficacy, with improvements in activities of daily living, muscle strength, and quality of life sustained through 60 weeks. Ultomiris was also well tolerated throughout…

During the second half of 2021, Scott was the top recipient of drug campaign cash in Congress

Sen. Tim Scott, a rising star in the Republican Party with broad popularity in his home state of South Carolina, is getting showered with drug industry money before facing voters this fall.

The U.S. Food and Drug Administration granted emergency use authorization to AstraZeneca’s COVID-19 antibody drug Evusheld on Dec. 8, 2021. Infectious disease physician Patrick Jackson of the University of Virginia explains how it works, who’s eligible and why some patients are having difficulties accessing it.